Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
Provectus Biopharmaceuticals (OTCQB: PVCT) has launched a preclinical study of its lead drug PV-10 for bladder cancer treatment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Provectus Biopharmaceuticals (OTCQB: PVCT) has launched a preclinical study of its lead drug PV-10 for bladder cancer treatment. The study, conducted by TD2, will evaluate both oral and intravesical monotherapy applications, as well as combination therapy with an anti-PD-1 checkpoint inhibitor.
The research aims to generate translational data to guide future clinical development and support broader immuno-oncology applications. Results are expected in Q1 2026. The study's findings will potentially enable expansion of PV-10's investigational new drug application for both site-specific and systemic administration.
Positive
- Potential expansion of PV-10's application to include both site-specific and systemic administration
- Study includes multiple treatment approaches (oral, intravesical, and combination therapy)
- Partnership with established research organization TD2 and City of Hope Cancer Center
Negative
- Results not expected until Q1 2026
- Early-stage preclinical study with no guaranteed success
- Multiple regulatory approvals still needed before commercialization
Details
News Market Reaction – PVCT
On Sep 29, the day this news came out, PVCT closed 2.63% above the previous close.
Data tracked by StockTitan Argus for the Sep 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead investigational drug PV-10 in an orthotopic bladder cancer model. Results are expected in the first quarter of 2026. PV-10 is formulated from the Company’s pharmaceutical-grade rose bengal sodium active pharmaceutical ingredient.
Conducted by Translational Drug Development, LLC (TD2), the study will evaluate PV-10’s performance across different treatment arms, including oral and intravesical monotherapy and combination with an anti-PD-1 checkpoint inhibitor. The study is designed to generate translational data that would inform future clinical development of PV-10 for bladder cancer and support broader immuno-oncology applications of oral PV-10 for solid tumor cancers.
Alan Bryce, MD, Interim President and Chief Clinical Officer, City of Hope Cancer Center Phoenix said, “Our goal is to be able to translate successful mouse model data into the foundation for a corresponding clinical trial of PV-10 in bladder cancer, with the key being to have an evidence basis for dose and route of administration determinations.”
Dominic Rodrigues, President and Vice Chair of the Board of Directors of Provectus, said “Successful results from this preclinical research will allow us to expand PV-10’s investigational new drug application for site-specific and systemic administration. We believe oral PV-10 has the potential to be a game-changing treatment across solid tumor and hematologic cancers.”
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing a pipeline of immunotherapy medicines based on rose bengal sodium, a first-in-class synthetic small molecule from the halogenated xanthene family. The Company’s clinical programs span oncology, dermatology, and ophthalmology, with additional proof-of-concept programs in hematology, wound healing, infectious diseases, and tissue repair.
For more information, visit www.provectusbio.com.
Forward Looking Statements
The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:
- The Company’s Annual Report on Form 10-K for the period ended December 31, 2024, and
- Provectus’s Quarterly Report on Form 10-Q for the period ended June 30, 2025.
Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
(866) 594-5999
Investor Relations & Media
Susan Xu
sxu@allianceadvisors.com
(778) 323-0959
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.